Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality -1% Improvement Relative Risk Ventilation 67% Progression 14% Progression (b) 42% Hospitalization 39% Hospitalization time -50% Recovery -1% Recovery time -8% c19early.org/cp Gharbharan et al. NCT04589949 Conv. Plasma RCT EARLY Favors conv. plasma Favors control
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial
Gharbharan et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.08.005, NCT04589949 (history)
23 Aug 2022    Source   PDF   Share   Tweet
RCT 416 outpatients in the Netherlands, showing no significant difference with convalesent plasma treatment. Hospitalization was lower, and improved results were seen with ≤5 days of symptoms, without statistical significance.
risk of death, 1.0% higher, RR 1.01, p = 1.00, treatment 1 of 207 (0.5%), control 1 of 209 (0.5%), day 28.
risk of mechanical ventilation, 66.6% lower, RR 0.33, p = 1.00, treatment 0 of 207 (0.0%), control 1 of 209 (0.5%), NNT 209, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 28.
risk of progression, 14.0% lower, OR 0.86, p = 0.42, treatment 207, control 209, adjusted per study, improved severity score, RR approximated with OR.
risk of progression, 42.0% lower, OR 0.58, p = 0.06, treatment 123, control 103, adjusted per study, improved severity score, ≤5 days, RR approximated with OR.
risk of hospitalization, 39.0% lower, HR 0.61, p = 0.22, treatment 10 of 207 (4.8%), control 18 of 209 (8.6%), NNT 26, adjusted per study, day 28.
hospitalization time, 50.0% higher, relative time 1.50, p = 0.56, treatment 207, control 209.
risk of no recovery, 1.0% higher, RR 1.01, p = 0.92, treatment 137 of 207 (66.2%), control 137 of 209 (65.6%), continued COVID-19 symptoms, day 27.
recovery time, 8.3% higher, relative time 1.08, p = 0.99, treatment 207, control 209.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gharbharan et al., 23 Aug 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Netherlands, peer-reviewed, 59 authors, study period November 2020 - July 2021, average treatment delay 5.0 days, trial NCT04589949 (history).
Contact: b.rijnders@erasmusmc.nl, a.gharbharan@erasmusmc.nl.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit